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Abstract
Background: Osteochondrosis (OC), simply defined as a failure of endochondral ossification, is a complex disease
with both genetic and environmental risk factors that is commonly diagnosed in young horses, as well as other
domestic species. Although up to 50 % of the risk for developing OC is reportedly inherited, specific genes and
alleles underlying risk are thus far completely unknown. Regions of the genome identified as associated with OC
vary across studies in different populations of horses. In this study, we used a cohort of Standardbred horses from
the U.S. (n = 182) specifically selected for a shared early environment (to reduce confounding factors) to identify
regions of the genome associated with tarsal OC. Subsequently, putative risk variants within these regions were
evaluated in both the discovery population and an independently sampled validation population of Norwegian
Standardbreds (n = 139) with tarsal OC.
Results: After genome-wide association analysis of imputed data with information from >200,000 single nucleotide
polymorphisms, two regions on equine chromosome 14 were associated with OC in the discovery cohort. Variant
discovery in these and 30 additional regions of interest (including 11 from other published studies) was performed
via whole-genome sequencing. 240 putative risk variants from 10 chromosomes were subsequently genotyped in
both the discovery and validation cohorts. After correction for population structure, gait (trot or pace) and sex, the
variants most highly associated with OC status in both populations were located within the chromosome 14
regions of association.
Conclusions: The association of putative risk alleles from within the same regions with disease status in two
independent populations of Standardbreds suggest that these are true risk loci in this breed, although population-
specific risk factors may still exist. Evaluation of these loci in other populations will help determine if they are specific to
the Standardbred breed, or to tarsal OC or are universal risk loci for OC. Further work is needed to identify the specific
variants underlying OC risk within these loci. This is the first step towards the long-term goal of constructing a genetic
risk model for OC that allows for genetic testing and quantification of risk in individuals.
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Background
Osteochondrosis (OC) is a commonly diagnosed devel-
opmental orthopedic disease that is defined as a focal
failure of endochondral ossification, the process by
which a cartilage template becomes bone in the limbs of
a growing animal [1]. It is characterized by the presence
of abnormal cartilage within a joint that may be thick-
ened, soft or collapsed or separated entirely from the
underlying bone. In the last case, the condition is com-
monly referred to as osteochondrosis dissecans (OCD)
[2]. OC is widely recognized in young horses across
breeds (as well as many other species) and is of particu-
lar interest because of its potential to cause joint effusion
and/or lameness in horses preparing for sales and enter-
ing training.
It has been postulated that OC could be caused by either
abnormal forces on normal cartilage or by normal forces
on abnormal cartilage [3], but the exact pathophysiology is
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not yet understood. Evidence from naturally-occurring dis-
ease and experimental models suggests that abnormalities
in vascular supply to the articular cartilage and subchondral
bone at anatomical predilection sites (i.e. within the tarsus,
stifle and fetlock) underlie the condition [4–6]. However,
alternative theories include abnormal extracellular matrix
maturation and inherited endoplasmic reticulum storage
disorders [7–9]. Additional contributing factors that have
been suggested include nutrition, exercise, conformation
and other biomechanical factors, trauma, stress response,
in utero environment and hormonal interactions [10–12].
While it is generally accepted that a combination of
genetic and environmental factors influence the devel-
opment of lesions, response to environmental manage-
ment alone is limited, highlighting the importance of
genetics in this disease [13–16].
The genetic contribution of OC risk has been quanti-
fied in a limited number of breeds considered particu-
larly prone to the condition, including Standardbreds
[17–19], French Trotters [20], Warmbloods [21–23], and
South German Coldbloods [24]. Based on these reports,
it can be estimated that between 15 and 52 % of the glo-
bal risk for developing OC can be attributed to genetic
factors. Variation in heritability estimates between popu-
lations is to be expected for any trait due to differences
in population history, gene frequency and environmental
exposures [25]. This is particularly true for OC since it
has known environmental interactions and likely has
multiple genetic alleles conferring susceptibility.
The presence of OC across domestic horse popula-
tions, including a feral horse population [26], as well as
shared major anatomical predilection sites and lesion
morphology [27], suggests a common underlying patho-
physiology and shared major genetic risk factors across
breeds. However, to date, the specific genes and alleles
underlying OC risk in the horse are completely un-
known. Genome-wide association studies (GWAS) have
been performed in a number of breeds using both
microsatellite markers and single nucleotide polymorph-
ism (SNP) beadchips (summarized in [28]). These stud-
ies and follow-up fine-mapping efforts [29, 30] have
identified multiple chromosomal loci that could poten-
tially contribute to the heritability of OC. However, the
findings have not been consistent across studies, and
only a single attempt to validate putative risk loci in a
second population has been reported [31]. Further, while
many potential candidate genes have been identified,
only one has been investigated [32], and a functional
allele conferring risk was not identified. The lack of
agreement in previous mapping studies may reflect con-
founding due to environmental risk factors and vari-
ability in phenotypic criteria for OC, or may represent
true population differences in risk alleles. Selection of a
study cohort made up of related individuals with a
shared early environment who all exhibit a similar
phenotype may help to address these potential limitations
of previous GWAS.
Here we describe the discovery of putative functional
variants and validation of risk loci underlying genetic
risk for tarsal OC in Standardbreds. Chromosomal re-
gions of interest were identified by genome-wide associ-
ation, enhanced by genotype imputation to a high SNP
density, in a discovery cohort of related Standardbred
yearlings born and raised on a single breeding farm in
the United States. Whole-genome sequencing was per-
formed for a subset of these individuals for the purposes
of variant discovery. Variants were then prioritized based
on predicted functional effect and segregation with OC
status. Selected putative functional variants were geno-
typed in both the discovery population and an independ-
ent validation cohort of Norwegian Standardbreds with
tarsal OC. This is the first report of specific putative risk
alleles associated with disease in two independent popu-
lations, and is an initial step towards the long-term goal
of developing a genetic risk model for OC that would
allow for genetic testing and quantification of risk in
individual horses.
Results
Genome-Wide Association (GWA) analysis
Horses in the discovery cohort (n = 182; 70 OC-affected,
112 unaffected) were genotyped on either the first- (Illu-
mina Equine SNP50) or second-generation (Illumina
Equine SNP70) equine SNP chip. In order to combine
data from the two platforms without loss of marker in-
formation, genotype imputation was performed using a
previously validated pipeline [33]. 61,046 markers were
available for GWA analysis. The mixed model analysis in
GEMMA, including sex and gait (pace or trot) as covari-
ates, revealed 12 SNPs, nine on ECA14 and one each on
ECA1, 10 and 21 that showed moderate evidence of
association with OC status (p ≤ 1.86 × 10−4 as deter-
mined by the likelihood ratio test) (Fig. 1 and Table 1).
The nine SNPs on ECA14 defined two distinct loci. Five
SNPs were loosely clustered between ~16.4 and 17.8 Mb
(with a slightly less significant hit at ~18.3 Mb), while
four SNPs defined a second region of interest be-
tween ~33.6 and 36.2 Mb. Forty-two named genes, 13
predicted pseudogenes and 3 non-coding RNAs were
located within the two regions of interest on ECA14
(Additional file 1: Table S1).
Haplotype analysis of the SNPs included in the GWA
was performed within the two regions of association
identified on ECA14. Within the region from ~16.4 to
18.3 Mb, nine haplotype blocks were identified, made up
of 2–8 SNPs and ranging in size from 8 bp to ~230 kb.
Haplotypes within three of these blocks were signifi-
cantly associated with OC (permuted p-value <0.05); a
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haplotype in a fourth block was moderately associated
with OC (permuted p-value 0.08). The overall fre-
quency of the three significantly associated haplotypes
ranged from 13.4 to 15.2 %, and they were more com-
mon in controls (17.8- 20.1 %) than cases (6.4–7.2 %).
Within the region from ~33.6 to 36.2 Mb, 22 haplo-
type blocks were identified, made up of 2–12 SNPs
and ranging in size from 4.6 kb to ~484 kb. A haplo-
type from a single block was significantly associated
with OC (permuted p-value 0.033), and haplotypes
from two additional blocks were moderately associated
with OC (permuted p-values 0.12–0.129). The fre-
quency of the significantly associated haplotype was
14.9 %, similar to the haplotypes in the other region;
however, it was more common in cases (22.5 %) than
controls (10.3 %). The two moderately associated hap-
lotypes from this region were present less frequently
in the population (5.8–6.9 %), but were also more
common in cases (10.1–11.6 %) than controls (3.1–
4 %) (Additional file 1: Table S2).
Two additional GWA analyses were performed in the
discovery cohort (n = 182) after imputation enabled by the
large SNP lists generated during development of the new
commercial equine SNP chip (see Methods). After pruning
in GEMMA, 123,352 and 243,115 markers from the 670 k
and 2 M sets, respectively, were available for inclusion in
the GWA analysis. Sex and gait were included as covariates
in the GEMMA mixed model. Analysis of the 670 k set re-
vealed 10 SNPs that showed moderate evidence of associ-
ation with OC status (p ≤ 3.3 × 10−5 as determined by the
likelihood ratio test). An additional 39 SNPs on 15 chro-
mosomes were within one order of magnitude of this sig-
nificance. Analysis of the 2 M set revealed 30 SNPs that
showed moderate evidence of association with OC status
(p ≤ 4.8 × 10−5 as determined by the likelihood ratio test).
An additional 66 SNPs on 16 chromosomes were within
one order of magnitude of this significance. The most sig-
nificantly associated SNPs in both analyses were all located
on ECA14, within the regions of interest defined by the
original GWA analysis (Additional file 1: Table S3).
Whole-genome sequencing
Twelve individuals (6 affected, 6 unaffected) were se-
quenced for a target of 6x coverage depth (actual coverage
4.7x to 7.9x; mean 6.4x). Six individuals (3 affected, 3 un-
affected) were sequenced for a target of 12x coverage
depth (actual coverage 10x to 13.1x; mean 12.2x). After
filtering, 14,588,812 variants were called, at an average of
1 variant every 162 base pairs. Of these, 13,157,608 were
SNPs, 671,144 were insertions and 760,060 were deletions.
The vast majority of variants, over 14 million (99.1 %),
were not predicted to have any functional effect. Of the
152,700 variants predicted to have some functional effect,
85,916 were of low impact (mostly synonymous SNPs),
57,122 were of moderate impact, and 9,662 were of high
impact (Additional file 1: Table S4).
Sequenom genotyping in the discovery cohort
Approximately 1.5 million variants were evaluated from
a total of 32 chromosomal regions that were either
Fig. 1 Manhattan plot of results from mixed model analysis using GEMMA. The 31 autosomal and X chromosome (32) are represented in
different colors along the x-axis and the –log (p-value) is on the y-axis. Each colored dot represents a SNP. Top hits are on ECA14. See Table 1 for
specific SNPs and p-values. The red horizontal line represents the level of genome-wide significance (p < 1.86 x 10-6); the blue line represents the
cutoff for moderate association (p < 1.86 x 10-4)
McCoy et al. BMC Genomics  (2016) 17:41 Page 3 of 11
identified as regions of interest in our GWAS or were
chromosomal regions previously reported to be associated
with tarsal OC (see Background and Additional file 1:
Table S5). Alleles were prioritized for follow-up according
to predicted functional effect and segregation with OC
status in the sequenced cohort. A high-throughput Seque-
nom genotyping assay was selected as the most efficient
way to evaluate a large number of prioritized alleles for as-
sociation with OC in a larger cohort. In total, 240 variants
on 10 chromosomes were genotyped in 180 horses from
the discovery population (Additional file 1: Table S6). An
additional 98 ancestry informative markers (AIMs) were
genotyped to use in construction of a mixed model ana-
lysis to control for population structure [34]. Genomic
heritability of OC, based on these markers, was estimated
to be 0.19 ± 0.38 (p < 0.001) on the binomial scale, or 0.10
on the underlying normal scale [35].
After pruning in GEMMA, 164 SNPs were available for
analysis. Sex and gait were included as covariates in the
model. The most significantly associated SNP (p = 4 × 10−4)
was located in the first intron of ARHGAP26 (Rho GTPase
activating protein 26) on ECA14 (chr14.34391965). The
alternate allele for this SNP was found in 20 % of cases
and 8 % of controls. Of the 23 variants with uncor-
rected p-values < 0.05, ten (p = 0.022–4 × 10−4) were lo-
cated within or immediately adjacent to the two ECA14
regions of interest identified in the GWAS (Table 2).
Although Sequenom SNPs were not chosen with regard
to their location relative to haplotypes in the GWA
data, four of these ten ECA14 SNPs (chr14.34391965,
chr14.18029925, chr14.18034557, chr14.18059791) were
located within the boundaries of haplotypes that were
significantly or moderately associated with OC (see
Genome-Wide Association (GWA) analysis).
Table 1 Top GWA SNPs from GEMMA mixed model analysis
Chr bp P-value likelihood ratio test
14 16401778 7.99E-06
14 34284113 1.43E-05
14 17858976 2.77E-05
14 17866794 2.77E-05
14 17626659 5.17E-05
10 56558910 8.32E-05
14 33630011 8.91E-05
21 54501469 1.51E-04
14 34366588 1.55E-04
14 17534553 1.64E-04
1 118288481 1.80E-04
14 36214363 1.83E-04
4 28769871 2.10E-04
21 48322513 2.51E-04
32 108097077 2.88E-04
10 58040174 3.07E-04
2 99965882 3.32E-04
10 72307543 3.89E-04
15 28682409 4.01E-04
24 38866310 4.13E-04
20 16930188 4.72E-04
2 61394335 4.78E-04
20 55342664 4.85E-04
16 50579676 4.93E-04
16 50839833 4.93E-04
16 51040831 4.93E-04
16 51098759 4.93E-04
28 26310499 5.01E-04
14 18305845 5.16E-04
SNPs in bold are moderately associated with
disease (1.86 × 10−6 < p < 1.86 × 10−4)
Chr chromosome, bp base pair
Table 2 Top SNPs from GEMMA mixed model analysis of
Sequenom genotyping data in the discovery cohort
Chr bp P-value likelihood
ratio test
Annotation
14 34391965 4.00E-04 Intron ARHGAP26
14 35363931 1.24E-03 Intron FCHSD1
14 16854653 2.23E-03 Synonymous exon 5 CCNG1
14 34803961 2.25E-03 Downstream SPRY4
14 37127327 2.25E-03 Downstream UBE2D2
10 57350466 2.28E-03 Intron PDSS2
14 18034557 5.97E-03 Intron GABRA1
10 55605051 6.27E-03 Downstream PREP
14 18059791 6.96E-03 Intron GABRA1
21 50348105 7.37E-03 Intron SEMA5A
14 16782922 9.55E-03 Synonymous exon 1 MAT2B
21 53443537 9.69E-03 Downstream ADAMTS1
14 18029925 1.13E-02 Synonymous exon 8 GABRA1
2 99999249 1.24E-02 Intergenic
21 48664783 2.20E-02 Intron CTNND2
14 18528304 2.22E-02 Intron GABRB2
10 57303131 2.23E-02 Intron PDSS2
21 50383063 2.58E-02 Intron SEMA5A
16 14358731 2.69E-02 Nonsynonymous exon 8 CNTN6
10 56817838 2.92E-02 Intron QRSL1
21 49882816 3.39E-02 Synonymous exon 1 TAS2R1
1 118771557 3.64E-02 Intron PPCDC
1 118401125 4.42E-02 Downstream SNUPN
Chr chromosome, bp base pair
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Sequenom genotyping in the validation cohort
Horses in the validation cohort (n = 139; 60 OC-affected,
79 unaffected) were genotyped using the same custom
Sequenom assay as the discovery cohort. After pruning
in GEMMA, 176 SNPs were available for analysis. As all
horses in this cohort were trotters, only sex was included
as a covariate in the model. The most significantly asso-
ciated SNP (p = 0.0014) was a missense mutation in exon
9 of GABRA6 (gamma-aminobutyric acid (GABA) A
receptor, alpha 6) on ECA14 (chr14.18198820). The
alternate allele for this SNP was found in 40 % of cases
and 23 % of controls, and it was located on the edge of a
haplotype found to be significantly associated with OC in
the GWA data from the discovery cohort (see Genome-
Wide Association (GWA) Analysis). Of the 14 variants
with uncorrected p-values < 0.05, four (p = 0.049–0.0014)
were from the ECA14 regions of interest identified in the
discovery cohort GWAS. Six variants were from regions
reported to be associated with OC in the published
GWAS for the validation cohort (ECA1 [n = 3], ECA3
[n = 1], and ECA5 [n = 2]) (Table 3) [36]. Interestingly, for
all but one of these six SNPs, the alternate allele was more
frequent in the unaffected horses (range 17–54 %) than in
the affected horses (range 8–33 %). In contrast, the alter-
nate allele for all four of the most significant ECA14 SNPs
was more common in the affected individuals (range 32–
40 % vs. 16–23 % in unaffected) (Additional file 1:
Table S7). SNPs with p < 0.05 from two other chromosomal
regions were shared between the two populations: ECA10
(~55.6–57.3 Mb) and ECA21 (~48.6–53.4 Mb). These re-
gions of interest were identified from the discovery
population GWAS, although they were less significantly as-
sociated with OC than the regions on ECA14 (Table 1).
Discussion
GWA analysis in our discovery cohort of U.S.
Standardbreds identified 12 SNP markers within two
different loci on ECA14 that were moderately associ-
ated (p ≤ 1.86 × 10−4) with OC status. These regions
have not been identified as significantly associated
with OC in any previously published GWAS (the
previously reported association on ECA14 in French
Trotters spanned a region from 67 to 79 Mb [37]).
This population differed from those in previous OC
GWAS in that there was a shared early environment
between cases and controls, thus reducing the con-
founding effects of management factors such as diet
and exercise. An additional advantage of this cohort
was that individuals were closely related, thus poten-
tially enhancing the number of risk alleles within the
population and improving the power of the GWA to
detect association with disease [38, 39]. However, the
sample size was still relatively limited, which may be
why genome-wide significance was not achieved. The
use of mixed model analysis in GEMMA allowed
both for correction for population structure [40]
using a marker-based relatedness matrix [41] and in-
clusion of covariates that may play a role in disease
development, such as gait [42].
SNPs are chosen for inclusion in genotyping panels
based on their distribution across the genome and their
frequency within the population rather than on their
locations within protein-coding genes. Of the five most
significantly associated SNPs in the GWAS reported
here (chr14.16401778, chr14.34284113, chr14.17858976,
chr14.17866794, chr14.17626659), three are in very large
introns and two are intergenic, so these SNPs are likely
“tagging” true risk variants with which they are in link-
age disequilibrium (LD) [43, 44]. Horses exhibit exten-
sive LD, and Standardbreds in particular have the
greatest long range LD (>1,200 kb) among horse breeds
[45]. Thus, it is reasonable that a SNP demonstrated to
be associated with disease in our GWAS could be
reflecting the effects of a risk variant up to 1 Mb dis-
tant (or farther) from that SNP marker. Due to the
large number of potential candidate genes within 1 Mb
of the regions of interest, and the extensive LD in
Standardbreds, we chose to perform whole-genome se-
quencing in a subset of our discovery cohort for variant
discovery. One advantage of this approach, beyond its
efficiency in cataloging both coding and non-coding
variants, was that it allowed variant discovery to be car-
ried out in eighteen horses, rather than just two or
three. This resulted in a more complete picture of what
variants were present in the population, as well as a
Table 3 Top SNPs from GEMMA mixed model analysis of
Sequenom genotyping data in the validation cohort
Chr bp P-value likelihood
ratio test
Annotation
14 18198820 1.41E-03 Nonsynonymous exon 9 GABRA6
3 107352236 1.57E-03 Nonsynonymous exon 20 PROM1
1 140205123 1.89E-03 Nonsynonymous exon 20 ATP8B4
1 139685697 2.82E-03 Nonsynonymous exon 32 TRPM7
14 16830511 5.34E-03 Intron HMMR
14 16840478 8.05E-03 Intron NUDCD2
4 5924012 9.70E-03 Nonsynonymous exon 4 ATXN7L1
21 48664783 1.13E-02 Intron CTNND2
10 57209370 1.83E-02 Downstream PDSS2
5 77536297 1.89E-02 Nonsynonymous exon 8 CLCA2
5 78709303 2.27E-02 Nonsynonymous exon 4 WDR63
1 139944477 4.16E-02 Nonsynonymous exon 10 SLC27A2
10 56817838 4.47E-02 Intron QRSL1
14 37281732 4.93E-02 Downstrream SPATA24
Chr chromosome, bp base pair
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better estimate of how these variants segregate with
disease status, which helped with prioritization for
follow-up in the larger group.
We investigated variants both within regions of the
genome corresponding to GWAS findings in our dis-
covery cohort as well as from selected additional re-
gions published by others as putative quantitative trait
loci (QTLs) for hock OC. Genomic heritability calcula-
tions indicate that together these variants explain 10–
20 % of the phenotypic variance for this trait. Overall,
SNPs from four loci on three chromosomes (ECA14, 10
and 21) were associated with disease status in both the
discovery and validation cohorts. The association of
putative risk alleles from within the same regions with
disease status in two independently sampled popula-
tions of Standardbreds suggest that these are true risk
loci in this breed. Population-specific risk factors may
still exist (i.e. variants on ECA1, 3 and 5 in the valid-
ation population) and will need to be investigated in
future studies.
Additional investigation of variants within the risk loci
on ECA14, 10 and 21 will need to be carried out in the
populations reported here to identify specific risk alleles.
There are several genes within the identified risk loci that
are plausible biologic candidates for playing a role in OC
and which contained variants that were highly associated
with disease in either the discovery or the validation cohort,
including MAT2B, HMMR, CCNG1 and ARHGAP26.
Methionine adenosyltransferase II beta (MAT2B) catalyzes
the synthesis of S-adenosylmethionine (SAMe). Methionine
is an essential amino acid in normal skeletogenesis [46],
and exogenous SAMe is utilized therapeutically for
osteoarthritis because of its beneficial effects on car-
tilage, including increased proteoglycan synthesis [47].
Hyaluronan-mediated motility receptor (HMMR) is a
hyaluronan-binding protein that has been identified in
epiphyseal cartilage, articular cartilage and interzone
cells (located in what will become the joint space) in
the developing joints of embryonic chicks, and is be-
lieved to play a major role in synovial joint formation
[48]. The role of cyclin G1 (CCNG1) in cartilage has
not been reported, but members of the cyclin family
have been reported to regulate chondrocyte prolifera-
tion [49, 50], and cyclin-dependent kinase inhibitors
have been shown to mediate growth arrest in chon-
drocytes [51]. GTPase activating proteins, such as rho
GTPase activating protein 26 (ARHGAP26), are cru-
cial mediators of the activity of Rho GTPases, which
play an important role in chondrocyte differentiation
and normal long bone development [52]. Clearly, vari-
ants in these genes will be of particular interest.
However, in addition to variants within or near
protein-coding genes, which have been our focus to
date, we may need to consider a possible role for
variants within non-coding/regulatory regions of the
genome as we move forward.
Conclusions
Here we report the discovery and validation of risk loci
on ECA14 for tarsal OC in Standardbred horses. Add-
itional putative risk loci were identified on ECA10 and
21, although these were less significantly associated with
disease status. Together, the investigated variants explain
10–20 % of the phenotypic variance of OC in the re-
ported population. This is the first report of a GWA
analysis in a cohort of horses specifically selected for a
shared early environment, the first to use imputation to
greatly increase the number of available genotypes in the
GWA population, and the first report validating putative
risk loci for equine OC in an independent population.
Further evaluation of these risk loci should be attempted
in Standardbreds with OC lesions in joints other than
the tarsus, and in another breed (i.e. Warmblood) af-
fected by tarsal OC. This would help to determine if the
identified risk loci are specific to the Standardbred
breed, or to tarsal OC or are universal risk loci for OC
(i.e. across all predilection sites and breeds).
Additional investigation is needed to identify the ac-
tual functional variants underlying disease risk within
the validated risk loci. This is the first step towards the
long-term goal of constructing a genetic risk model for
OC that allows for genetic testing and quantification of
risk in individual horses. This risk model could contain
as many as 6–15 putative risk alleles, similar to those
that have been used successfully to predict recurrence
and survival in patients with breast cancer, another gen-
etically complex disorder [53]. Improved risk assessment
will facilitate management changes and early interven-
tion in high-risk horses and allow for informed breeding
decisions in high-risk pedigrees that will ultimately help
to reduce disease prevalence.
Methods
GWAS discovery cohort
This study was conducted under the approval of the
University of Minnesota Institutional Animal Care and
Use Committee (protocol #1111B07139). The discovery
cohort was comprised of 182 Standardbred yearlings
born and raised on a single breeding farm in the eastern
United States. Individuals were included from the 2007
(n = 94), 2009 (n = 16), 2010 (n = 52), and 2012 (n = 20)
foal crops. Management practices, including diet and ex-
ercise regimen, were the same for all foals at this facility
during their first year of life. Average prevalence of tarsal
OC on this farm for the included foal crops was 28 %.
Yearlings were identified for inclusion in this study dur-
ing preparation for one of several breed-recognized sales
events. Affected horses (n = 70) had surgically-confirmed
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OC lesions of one or both tarsi. Of the 112 age-matched
related controls, 78 were radiographically confirmed to
be free of tarsal OC, while 34 (from the 2007 foal crop)
were presumed unaffected because of lack of clinical
signs including effusion and lameness.
DNA isolation and whole-genome genotyping
DNA was isolated from blood (2007 and 2012 foals) or
hair roots (2009 and 2010 foals) samples using the
Gentra® Puregene® Blood Kit (Qiagen, Valencia, CA) per
manufacturer recommendations. Briefly, for blood sam-
ples, RBC lysis solution was added to samples at a 3:1
ratio, incubated and centrifuged. After discarding the
supernatant, cell lysis solution was added to the white
blood cell pellet and the cells were re-suspended, after
which protein was precipitated and discarded. DNA was
precipitated in isopropanol and subsequently washed in
ethanol prior to final hydration. A similar protocol was
followed for hair root samples, omitting the RBC lysis
step. Quantity and purity of extracted DNA were assessed
using spectrophotometric readings at 260 and 280 nm
(NanoDrop 1000, Thermo Scientific, Wilmington, DE).
Genome-wide genotyping of single nucleotide poly-
morphism (SNP) markers was performed by Neogen
GeneSeek (Lincoln, NE) using the Illumina Custom
Infinium SNP genotyping platform. Samples from the
2007 foal crop were genotyped at 54,602 SNPs using the
first generation Illumina Equine SNP50 chip, while the
remaining samples were genotyped at 65,157 SNP
markers using the second generation Illumina Equine
SNP70 chip.
Genotype imputation
The two equine genotyping platforms used in the dis-
covery population share 45,703 SNPs. This shared set of
markers can be extracted and the files merged into a sin-
gle data set, but data from tens of thousands of markers
is lost. Genotype imputation is a technique that statisti-
cally estimates genotypes from non-assayed SNPs by
comparing haplotype blocks in the study population
with haplotype blocks in a more densely genotyped ref-
erence population. A pipeline for imputation of equine
genotyping data was established and validated utilizing
BEAGLE (version 3) [54] software for imputation [33].
Using this pipeline, imputation was performed in the
2007 cohort for the ~18,000 markers unique to the
Equine SNP70 chip, while imputation was performed in
the remaining samples for the ~9,000 markers unique to
the Equine SNP50 chip. Resulting imputed files were
merged with the original data files using the –merge
command in PLINK [55].
A new custom equine genotyping platform containing
~670,000 SNPs (670 k; Affymetrix Axiom Array) became
available commercially in January 2015. These SNPs
were selected from an initial list of ~2 million SNPs
identified by whole-genome sequencing in 166 horses
from 32 diverse breeds [56]. Imputation using BEAGLE
(version 4.0) as described above was performed for the
entire discovery cohort, using a mixed breed reference
population (n = 513) in a stepwise fashion. First, the
original SNP50/SNP70 data was imputed to the SNPs
included in the new 670 k array. SNPs from this step
were then pruned to those correctly called > 95 % of the
time in horses genotyped on both platforms (SNP50/
SNP70 and 670 k; n = 40) and subsequently imputed to
2 million SNPs. These SNPs were again pruned at > 95 %
concordance for use in analyses.
Genome-Wide Association (GWA) analysis
Initial GWA analysis was carried out after imputation
(between the SNP50 and SNP70 chips) using GEMMA
(Genome-wide Efficient Mixed Model Analysis) software
[57]. The GWA was performed using the options to cre-
ate a centered relatedness matrix (−gk 2) and perform
all three possible frequentist tests: Wald, likelihood ratio
and score (−fa 4). A covariate file (−c) including sex and
gait (pacer or trotter) was incorporated into the mixed
model. The relatedness matrix was incorporated to con-
trol for family structure among the discovery cohort and
was constructed using a linkage-disequilibrium (LD)-
pruned set of markers from the imputed genome-
wide SNP data (100 SNP windows, sliding by 25
SNPs along the genome, pruned at r2 > 0.2; PLINK
command –indep-pairwise 100 25 0.2) [45]. SNPs were
pruned prior to GWA using the default GEMMA parame-
ters of MAF < 1 % and missingness < 95 %. The genome-
wide significance cutoff using an adjusted Bonferroni
correction based on the effective number of independent
tests in our data was p <1.86 × 10−6 [58]. P-values between
1.68 × 10−4 and 1.68 × 10−6 were considered to indicate
moderate association.
Haplotype analysis was conducted on 61,046 marker
set (used in the GEMMA analysis described above)
using Haploview [59]. Haplotype blocks were con-
structed (− blockoutput) using the default algorithm
taken from Gabriel et al. [60], which is based on
95 % confidence bounds on D prime. Case control as-
sociation testing (− assocCC) was performed with
1000 permutations (− permtests 1000). Permuted associa-
tions were considered statistically significant at p < 0.05.
Whole-genome sequencing
Individuals were selected for whole-genome sequencing
on the basis of haplotype analysis within regions of inter-
est on equine (ECA) chromosomes 2, 6 and 14. Haplo-
types were evaluated for both their absolute frequency
within the OC-affected and OC-unaffected groups and for
differences in frequency between groups. For each region,
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the most common haplotype within an affectation
status that also exhibited a large difference between
OC-affected and OC-unaffected groups was selected as
the haplotype of interest. Individuals that exhibited
these haplotypes in one or more of the regions of inter-
est were eligible for selection for whole-genome se-
quencing. Horses were preferentially selected if they
had the haplotype of interest in more than one region
of interest; however, consideration was also given to
balancing the selected cohort by sex, gait (pace or trot)
and sire to manage potential confounding factors.
Genomic DNA (2–6 μg) from the 18 selected horses
was submitted to the University of Minnesota Biomedical
Genomics Center (UMGC) for quality control, library
preparation and sequencing. Samples were subjected to
library preparation including fragmentation, polishing,
and adaptor ligation and were prepared with an indexed
barcode for a 100 bp paired-end run on the Illumina
HiSeq sequencer, per standard protocols. Of the nine
affected horses, 3 were sequenced at 12x coverage and 6
at 6x coverage; the same distribution was used for the nine
unaffected horses.
Data analysis, including quality control, alignment and
variant detection, was carried out following published
best practices [61] within the Galaxy framework hosted
by the Minnesota Supercomputing Institute. Briefly,
reads that passed quality control were mapped to the
reference sequence (EquCab 2.0, Sept. 2007) using BWA
for Illumina. Ambiguously mapped reads, low quality
reads and PCR duplicates were removed, after which
reads were realigned around indels. Base quality recali-
bration was performed to remove systematic bias. This
process was completed for the reads from each of the
eight lanes for every individual before merging the
mapped and recalibrated “lane-level” BAM files into a
single “sample-level” file. Removal of duplicates and re-
alignment around indels was repeated on the merged
file. The eighteen sample-level files were merged into
three groups of six, evenly divided between affected and
unaffected individuals, for the purposes of variant calling
using the UnifiedGenotyper utility of the Broad Institute’s
Genome Analysis ToolKit (GATK) with a threshold
phred-scale score of 20.0. Variants were filtered using the
following thresholds: Quality Depth (QD) < 2.0 (assesses
variant quality score taking into account depth of coverage
at that variant), Read Position Rank Sum < −20.0 (Mann-
Whitney Rank Sum test on the distance of the variant
from the end of each read covering it), Fisher Strand
(FS) > 200.0 (phred-scaled p-value to detect strand bias).
Filtered variant lists from the three groups were combined
into a single variant calling file (VCF) for subsequent ana-
lysis. Predicted functional effect for each called variant
was determined based on the current equine reference
genome annotation using SnpEff [62]. Frequency of
variants within cases and controls, and the significance of
frequency differences, was calculated using SnpSift Case-
Control [63]. Variants from particular chromosomal re-
gions of interest were selected using SnpSift Intervals and
converted into Excel format for further evaluation.
Sequenom assay
A custom Sequenom assay was designed for high-
throughput genotyping of prioritized variants. Variants
were selected from within the top chromosomal regions
of interest from the GWA in the discovery cohort as well
as from chromosomal regions previously reported to be
associated with hock OC (see Background). Variants dis-
covered through whole-genome sequencing were filtered
to include SNPs that passed all quality control filters, and
were subsequently prioritized according to the following
parameters: 1) present in 3+ more cases than controls, or
vice versa; 2) not intergenic; 3) non-synonymous, then
synonymous changes; 4) if intronic, close to intron-exon
boundary (preferably <100 bp); 5) coding genes preferred
over non-coding; and 6) if upstream/downstream, as close
as possible to start/stop codon.
An attempt was made to include at least one variant
per coding gene within each region of interest; if mul-
tiple variants of equally low predicted function were the
only ones available within a gene, then the one with the
higher genomic p-value was selected. In addition to the
experimental SNPs, 98 ancestry informative markers
(AIMs) were included in the Sequenom assay to help
control for population structure [34]. The AIMs used in
this study were generated from a large population of
gaited horses, including Standardbreds and capture
97.6 % of the variation captured by significant principal
components from genome-wide genotyping data.
Genotyping results were analyzed using the GEMMA
parameters described previously (see Genome-Wide
Association (GWA) Analysis). The relatedness matrix
was constructed using the AIMs.
To determine the relative amount of phenotypic vari-
ation explained by prioritized variants, genomic heritabil-
ity was etimated using a genomic best linear unbiased
predictor (GBLUP) analysis (SNP & Variation Suite 8,
Golden Helix, Bozeman, MT). Assuming an additive
genetic model, GBLUP uses a genomic relationship matrix
(GRM) derived from genotype data to predicts allele
substitution effects of each marker and additive genetic
effect of each individual [64]. Covariates of sex and gait
were included in the GBLUP analysis.
Validation cohort
The horses included in the validation cohort have been
described in detail by Lykkjen et al. [36] This population
included 162 Norwegian Standardbred trotter yearlings
belonging to 22 half-sibling families that were identified
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as either affected or unaffected with tarsal OC based on
survey radiographs taken between 8 and 18 months of
age (mean 12.1mo). Horses with simultaneous lesions in
the fetlock were removed so that the OC phenotype
would be comparable to the discovery population, result-
ing in a final validation cohort of 139 horses (60 cases,
79 controls). These horses were genotyped on the
custom Sequenom assay (see Sequenom assay), which
included SNPs from chromosomal regions of interest
previously reported in a GWA in this same population
(ECA1 and 3). Genotyping results were analyzed using
the GEMMA parameters described previously (see Gen-
ome-Wide Association (GWA) Analysis). The relatedness
matrix was constructed using the AIMs.
Availability of supporting data
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